Archives: Agenda

• Introduction
• VISIONAL™ Overview
  • Cloud-based module for tailored feasibility data processing
• Machine-Learning Study Tool
  • Models and compares country/site combos in minutes
  • Forecasts enrollment, considering costs and success probability
• Efficiency, Power, Results
• Conclusions

• Highlighting trends in trial designs used within oncology trials that successfully met their recruitment targets.
• Exploring the effect of trial design on subject drop-out rates and comparing drop-out rates in the East Coast to global trials through case studies.
• Using historical oncology trial data to explore the difference between the ratio of subjects to sites in completed vs terminated oncology trials.
• Using case studies to compare the project outlook, timelines, and expected enrolment, between the East Coast and global oncology trials.

• Highlighting common issues between sponsors and vendors to maintain a better relationship
• Emphasizing importance on trust and communication to enhance results from CROs
• What foundations do sponsors require from CROs to obtain an effective partnership?

• How are “live reads” actually defined?
• Value of performing live reads
• Operationalizing live reads
• Is there any downside to live reads?
• When are live reads best utilized?

• Investigating how venture capitalists can aid sponsors with oncology trials in the long term
• Exploring avenues available to sponsors in order to source investment for oncology trials
• How can sponsors strategize new ways to attract investors for research and oncology trial development?

• Reviewing the past and current barriers to improving patient enrollment and retention amidst the unique complexities of today’s oncology clinical trials
• Researching the research:  Exploring key takeaways from patient educational support case studies
• Employing multimodal educational approaches and varied communication channels to enhance patients’ informed engagement

• Exploring new modalities and platforms to support new generation gene and cell therapies
• What can we learn from current clinical and translational evidence thus far from cell therapies that were successful?
• Determining whether cell and gene therapies are the best solutions to implement in specific oncology indications

• Highlighting importance of site management to increase trial success
• Evaluating struggles in site relationships and what are the solutions to streamline selection and balance relations?
• Investigating strategies to maximize patient recruitment at selected sites